TCT-569 Lower mortality after clinically significant bleeding in patients treated with reversible P2Y12 agent Ticagrelor: A comparative, all-comers, prospective, 2-year follow up study in patients treated with invasive strategy after acute coronary syndrome

Girish Viswanathan,James Russel,Nadia Dullaghan,Sotirios Dardas,Amit Taneja,Shabnam Venkat

TCT-569 Lower mortality after clinically significant bleeding in patients treated with reversible P2Y12 agent Ticagrelor: A comparative, all-comers, prospective, 2-year follow up study in patients treated with invasive strategy after acute coronary syndrome

2018

Girish Viswanathan
James Russel
Nadia Dullaghan
Sotirios Dardas
Amit Taneja
Shabnam Venkat

Reversible P2Y12 inhibitor Ticagrelor have theoritical advantage of improved outcomes after bleeding episodes compared to irreversible P2Y12 inhibitors namely prasugrel and clopidogrel after acute coronary syndrome (ACS). Data on combined net adverse events (NAE) of mortality after bleeding and

Keywords:

Ticagrelor
Diabetes mellitus
Acute coronary syndrome
P2Y12
Medicine
Cardiology
Internal medicine
Prasugrel
follow up studies
Adverse effect
Clopidogrel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations